相似文献
1
CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy.
Hum Vaccin Immunother. 2022 Dec 31;18(1):2024416. doi: 10.1080/21645515.2021.2024416. Epub 2022 Feb 7.
2
CIMT 2022: Report on the 19th Annual Meeting of the Association for Cancer Immunotherapy.
Hum Vaccin Immunother. 2022 Nov 30;18(6):2124785. doi: 10.1080/21645515.2022.2124785. Epub 2022 Oct 12.
3
CIMT 2018: Pushing frontiers in cancer immunotherapy - Report on the 16 Annual Meeting of the Association for Cancer Immunotherapy.
Hum Vaccin Immunother. 2018;14(12):2864-2873. doi: 10.1080/21645515.2018.1504526. Epub 2018 Aug 29.
4
CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer Immunotherapy.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2381925. doi: 10.1080/21645515.2024.2381925. Epub 2024 Jul 23.
5
CIMT 2019: report on the 17th Annual Meeting of the Association for Cancer Immunotherapy.
Hum Vaccin Immunother. 2020 Apr 2;16(4):808-815. doi: 10.1080/21645515.2019.1675459. Epub 2019 Nov 11.
6
CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.
Hum Vaccin Immunother. 2017 Oct 3;13(10):2272-2279. doi: 10.1080/21645515.2017.1358327.
7
CIMT 2016: Mechanisms of efficacy in cancer immunotherapy - Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10-12 2016, Mainz, Germany.
Hum Vaccin Immunother. 2016 Nov;12(11):2805-2812. doi: 10.1080/21645515.2016.1206677. Epub 2016 Jul 19.
8
CIMT 2023: report on the 20th Annual Meeting of the Association for Cancer Immunotherapy.
Immunooncol Technol. 2023 Sep 12;20:100397. doi: 10.1016/j.iotech.2023.100397. eCollection 2023 Dec.
9
CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.
Hum Vaccin Immunother. 2014;10(10):3090-100. doi: 10.4161/hv.29767.
10
CIMT 2013: advancing targeted therapies--report on the 11th Annual Meeting of the Association for Cancer Immunotherapy, May 14-16 2013, Mainz, Germany.
Hum Vaccin Immunother. 2013 Sep;9(9):2025-32. doi: 10.4161/hv.25768. Epub 2013 Jul 22.
本文引用的文献
1
Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons.
N Engl J Med. 2021 Dec 23;385(26):2489-2491. doi: 10.1056/NEJMc2102507. Epub 2021 Dec 1.
2
T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes.
Nat Biotechnol. 2022 Apr;40(4):488-498. doi: 10.1038/s41587-021-01089-x. Epub 2021 Dec 6.
3
Impact of SARS-CoV-2 variants on the total CD4 and CD8 T cell reactivity in infected or vaccinated individuals.
Cell Rep Med. 2021 Jul 20;2(7):100355. doi: 10.1016/j.xcrm.2021.100355. Epub 2021 Jul 2.
4
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study.
Lancet Infect Dis. 2021 Nov;21(11):1507-1517. doi: 10.1016/S1473-3099(21)00290-5. Epub 2021 Jun 23.
5
SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021.
Int J Infect Dis. 2021 Jul;108:145-155. doi: 10.1016/j.ijid.2021.05.040. Epub 2021 May 19.
6
BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants.
N Engl J Med. 2021 Jul 29;385(5):472-474. doi: 10.1056/NEJMc2106083. Epub 2021 May 12.
7
Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees.
Clin Infect Dis. 2022 Jan 29;74(2):366-368. doi: 10.1093/cid/ciab411.
8
Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.
Front Immunol. 2021 Mar 3;12:640082. doi: 10.3389/fimmu.2021.640082. eCollection 2021.
9
Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.
Lancet. 2021 Mar 20;397(10279):1075-1084. doi: 10.1016/S0140-6736(21)00238-5.
10
Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February.
Euro Surveill. 2021 Mar;26(11). doi: 10.2807/1560-7917.ES.2021.26.11.2100256.
Zotero 插件